Onderneming Acerus Pharmaceuticals Corporation
Aandelen
ASPCF
CA00444G4051
Farmaceutische producten
Vakgebied
Aantal werknemers: 14
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Edward Gudaitis
CEO | Chief Executive Officer | - | 01-05-18 |
Naveed Manzoor
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 17-07-20 | |
Philippe Savard
LAW | General Counsel | - | 04-07-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 74 | - | |
Ian Ihnatowycz
CHM | Chairman | 71 | 09-09-13 |
Borys Chabursky
BRD | Director/Board Member | - | 20-12-15 |
Edward Gudaitis
CEO | Chief Executive Officer | - | 01-05-18 |
Stephen Gregory
BRD | Director/Board Member | - | 14-07-11 |
Geoff Cotton
BRD | Director/Board Member | - | 01-05-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 7 702 297 | 662 312 ( 8,599 %) | 0 | 8,599 % |
Bedrijfsgegevens
Acerus Pharmaceuticals Corp.
7025 Langer Drive Suite 205
L5N 0E8, Mississauga
+
http://www.aceruspharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,74% | 723 mld. | |
+34,31% | 595 mld. | |
-2,07% | 369 mld. | |
+20,25% | 332 mld. | |
+2,99% | 282 mld. | |
+17,06% | 244 mld. | |
+9,82% | 208 mld. | |
-4,34% | 205 mld. | |
+2,81% | 168 mld. |